Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R)...(will be treated with their physician'sch...),Health

Date:12/3/2008

will be treated with their physician's choice of either of two chemotherapy agents, dacarbazine or temozolomide. The primary endpoint is a variation of progression-free survival, specifically comparison of objective response rates at six months or more after randomization. The study will also evaluate safety and tolerability as well as overall survival. A patient self-screening tool for trial eligibility is available online at www.melanomaclinicaltrial.com.

About Metastatic Melanoma

The American Cancer Society has estimated that more than 62,000 new diagnoses of, and approximately 8,400 deaths from, melanoma will occur in 2008 in the United States. Currently, there are no consistently effective therapies for advanced cases of metastatic melanoma where the cancer has spread to other parts of the body. The toxicity associated with FDA-approved treatments such as dacarbazine or interleukin-2 is often significant, resulting in serious or life-threatening side effects in many of the patients treated. Patients with metastatic melanoma often are treated off-label with drugs such as temozolomide, which has been approved by the FDA for the treatment of certain types of brain cancer but not for the treatment of metastatic melanoma. Temozolomide is an orally-delivered pro-drug that converts in the body into the same active compound as dacarbazine.

About EIP

EIP is part of the Eczacibasi Group, a prominent Turkish industrial group of companies primarily involved in healthcare, consumer products, and building products. EIP focuses on sales and marketing of imported pharmaceuticals in specific therapeutic areas and has multiple licensing agreements with leading biotech and pharmaceutical companies.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologie
'/>"/>

SOURCE Vical Incorporated Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
2. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
3. U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vicals Vaxfectin(R) Adjuvant
4. Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
5. First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervical Disease
6. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
7. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
8. Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
9. Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
10. Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial
11. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders